Investment Q&A

Q: Hi Peter, I'm just wondering about any new views since the 3rd of Sept comment. Would this also be a good play on the vaccine investments for 2021. Each person needs 2 doses - that's a lot of syringes and needles! Would Becton benefit or is there too many competition suppliers out there (market share?) and/or doesn't make too much towards its total annual profits? Thanks.

Q: I would like your opinion on this little stock as it seems to be heading in the covid direction. Thx J

Q: Hi - huge pop on the IPO for AbCellera. Sounds promising, what would your take be on investing in it now? Better to wait for some of the enthusiasm to die down? Looks like it has a strong US following.

Q: I read that GUD would be delisted from S&P/TSX. What would be the reasons? Any suggestion?

Q: What portion of FHI distribution is return of capital? What would be your order of choice among LIFE; FHI; and HHL ?

Q: Can you comment on any recent insider buying or selling for GUD. E.g. has the CEO bought any large chunks? I am curious if there has been some insider purchasing/selling either before or after the shelf filing. If there has been buying, what do you think are the odds that there might be an acquisition in the works. I bought GUD at $5 and am trying to decide whether to hold, sell, or top up. Because everything else in my portfolio has done so well this year (all fantastic 5i suggestions), GUD has decreased to 1.3% of total holdings.

Q: Hi guys. Would you be able to tell me your ratings on these medical stocks for growth and risk please. It would be a 3 year time frame minimum. Thks again for the great job you do.

Q: Hello 5i
Could I have your opinion in PNSL please?
Also who would their competitors be?
Thank you
Dave

Q: GUD has roughly 400M in cash. Getting 360M with a share offering will get them 760M.
With that money how big an acquisition could it be if that was their intention ? Also, how long does it take normally take for for the shelf prospectus to be approved ?
Thanks

Q: Did not see the financing coming. My take is that they might be close to a deal and want to be able to act quickly. Perhaps impatient optimism? Your thoughts?

Q: I HAVE HELD THESE STOCKS FOR ALMOST YEAR AND A HALF, HOPING THE STOCKS WILL MOVE UP AS THE VACCINES BECOME AVAILABLE. I FIND THAT NONE OF THESE STOCKS HAVE MOVED UP EXCEPT VEEV, AND THAT TOO MARGINALLY. SHOULD I KEEP THESE STOCKS OR SELL THEM AND USE THE MONEY FOR OTHER PROMISING TECH STOCKS. THANKS

Q: I have a DOY balanced portfolio (Alpha-Balanced for guidance) , with less than 10 year timeframe.
I’m underweight communication services, and energy. Not a fan at this stage of oil or precious metals. Overweight in industrials and technology.
My concern is with my overweight in technology. Reading a number of opinion articles that refer to the tech boom as another dot.com. The reply often is oh but this is different.
Here’s my two cents worth especially related to tech stocks I own. First of all investors/traders seem to be jumping in and out of technology based on the latest COVID-19 / vaccine news.
Re KXS; will still be in demand long after Covid-19. LSPD; somewhat sensitive to Covid-19 but have done a good job diversifying and adapting restaurant services etc. Will do well in recovery.
Maybe more acquisitions.
SHOP; like Amazon will carry on even though the valuation is high. Younger generation will still shop on line.
Now comes the tricky part. WELL and VEEV. I don’t quite have a handle on. Not sure if the demand for their service will still be there post COVID-19.
Your comments and/or thought would be greatly appreciated. I have a feeling that many of your clients would be interested in what you have to say.
I’m an experienced investor but don’t have access to the kinds of info I once did. I depend a great deal on your unbiased expert opinion.
Merry Christmas

Roy

Q: Atara Biotherapeutics (NASDAQ:ATRA) has announced presentation of preclinical data of ATA3219 at American Society of Hematology.
Their allogeneic CAR T-cell therapy targeting CD19, Bayer has also just entered into an exclusive worldwide license agreement, for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors with Atara.
What is your opinion on this company and it's medium and long term investment potential.

Q: Good morning, I have a watch-list of vaccines, but it seemed like such a gamble in the past months, I didn't invest in any. Now that some are successful, I would like to have a position in at least one company. I've named a few above, but there are more. With the goal of growth in the next 1-2 years, which one or two "vaccine" stocks would you choose, and what percentage of the portfolio would you suggest as investment size. Thank-you.

Q: Moderna's stock has gone up significantly over the last few months. Is it a good time to sell? would love to hear your thoughts about it. Thank you!

Q: Is this a buy at the moment in regards to its vaccine.

Q: I've been watching REGN slide from US$650 to under US$500 over the last few months. Is it just out of favour? The metrics seem ok (for a biotech) and analysts still seem to like it. What's your opinion on opening a position under $500? Thanks.

Q: Please comment on latest acquistion of Excellemd today. Txs for u usual great services & views

Q: Hi there,

DMTK I came across DermTech listening to a MF US stock advisor live session on 10X opportunities. I spent some time reviewing their most recent earnings transcript and other research and the technology for non invasive detection of skin cancer seems powerful but super early in terms of adoption (a brief excerpt is below). I am considering buying for TFSA and have the following questions:
1. What is your general opinion?
2. Do you have any information on how a dermatologist would be paid for using this test vs surgery? My fear would be that the tech is amazing but dermatologists may not use it if it would reduce their revenue

"Currently, approximately 25 surgical biopsies are performed to find one melanoma. And despite all this cutting, the negative predictive value of this pathway is only about 83%, which means the probability of missing melanoma is approximately 17%. The PLA reduces the number of surgical biopsies needed to identify melanomas by approximately 10-fold and increases the negative predictive value so 99%, meaning the PLA has less than 1% probability of missing the disease. DermTech is effectively bringing melanoma diagnosis into the 21st century by transforming it from a pathway to subjective, invasive, inaccurate and costly to one that is objective, non-invasive, highly accurate, and less costly."

Q: Hi,

Of these relatively new biotech companies that have or will soon be IPO'ing, Repare Therapeutics (June IPO) and Abcellera Biotech (upcoming IPO), where would you put some play money? A bit of both? Or another recent IPO/choice altogether?
It seems that Abcellera might be a little ahead of the game wrt being profitable already. And I'm pretty sure given the expected interest, I may have to get this initially on the open market.
Are there any things from a finance view we should be aware of with these IPO's other than biotechs can be more risky dependent on clinical trial results, etc..
Repare has done well since its IPO in June.
Can you pls also add Repare to your db? It did not come up in a text or stock symbol search.

Cheers,
SteveMc